Periprocedural bridging anticoagulation: current perspectives.
Research article published in American journal of therapeutics (2011)
Abstract
Perioperative management of patients on chronic anticoagulant use involves balancing individual risk for thromboembolism and bleeding. Discontinuation of antithrombotic therapy can place patients at increased risk of thromboembolic complications, whereas continuing antithrombotic therapy can increase procedure-related bleeding risk. Temporary perioperative substitution of low-molecular weight heparin or unfractionated heparin in place of warfarin, "the bridge therapy" is often used in the periprocedural period, but the indications and timing of this is still uncertain. This review addresses the risk stratification of patients according to thromboembolic risk, indications, timing, and duration, and a practical approach to bridge therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Periprocedural bridging anticoagulation: current perspectives.
Why This Matters for Hirudotherapy
This review addresses the risk stratification, indications, timing, and practical approaches to periprocedural bridging anticoagulation, which involves substituting heparin for warfarin temporarily. It focuses on balancing the risks of thromboembolism and procedure-related bleeding during invasive procedures. There is no defensible link to hirudotherapy, the leech secretome, or the American Society of Hirudotherapy's domain. The abstract focuses strictly on conventional medical management with warfarin and heparin. No leeches, hirudin, or related therapies are mentioned or implied in the text, making it entirely irrelevant to the society's focus.
Citation
Periprocedural bridging anticoagulation: current perspectives.
Palaniswamy et al. · American journal of therapeutics, 2011
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026